101 – 200 of 329
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2014
-
Mark
A longitudinal study of family structure in Swedish persons with haemophilia.
(
- Contribution to journal › Article
-
Mark
Methods for individualising factor VIII dosing in prophylaxis
(
- Contribution to journal › Scientific review
-
Mark
Desmopressin in treatment of haematological disorders and in prevention of surgical bleeding.
(
- Contribution to journal › Scientific review
-
Mark
Pharmacokinetics, phenotype and product choice in haemophilia B: how to strike a balance?
(
- Contribution to journal › Article
-
Mark
Outcome measures in haemophilia: a systematic review
(
- Contribution to journal › Scientific review
-
Mark
A comparison of the treatment of patients with factor IX deficiency to that of those with factor VIII deficiency: results of an International Survey conducted as part of the International FIX Treatment Network.
(
- Contribution to journal › Letter
-
Mark
Clotting factor level is not a good predictor of bleeding in carriers of haemophilia A and B.
(
- Contribution to journal › Article
-
Mark
Textbook of hemophilia : Care of the child with hemophilia
2014) p.145-150(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Clinically relevant non-neutralizing anti-FVIII antibodies in a hemophiliac
(
- Contribution to journal › Letter
- 2013
-
Mark
Long-term anti-FVIII antibody response in Bethesda-negative haemophilia A patients receiving continuous replacement therapy.
(
- Contribution to journal › Article
-
Mark
Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN)
(
- Contribution to journal › Article
-
Mark
Increased burden on caregivers of having a child with haemophilia complicated by inhibitors.
2013) In Pediatric Blood & Cancer(
- Contribution to journal › Article
-
Mark
The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort.
(
- Contribution to journal › Article
-
Mark
Thrombosis in patients with hemorrhagic disorders.
(
- Contribution to journal › Article
-
Mark
Pharmacokinetics of plasma-derived and recombinant factor IX: using population pharmacokinetics with sparse sampling data needs further study.
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Incidence, mortality rates and causes of deaths in haemophilia patients in Sweden.
(
- Contribution to journal › Article
-
Mark
F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort
(
- Contribution to journal › Article
-
Mark
Intermediate- dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s
(
- Contribution to journal › Article
-
Mark
Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study
(
- Contribution to journal › Article
-
Mark
History of prophylaxis.
(
- Contribution to journal › Article
-
Mark
Third Åland islands conference on von Willebrand disease, 26-28 September 2012: meeting report.
(
- Contribution to journal › Article
- 2012
-
Mark
Differences between developed and developing countries in paediatric care in haemophilia
(
- Contribution to journal › Article
-
Mark
Quality of life in adult patients with haemophilia - a single centre experience from Sweden.
(
- Contribution to journal › Article
-
Mark
Management of bleeding disorders in children
(
- Contribution to journal › Scientific review
-
Mark
A prospective registry of European haemophilia B patients receiving nonacog alfa, recombinant human factor IX, for usual use.
(
- Contribution to journal › Article
-
Mark
Daily dosing prophylaxis for haemophilia: a randomized crossover pilot study evaluating feasibility and efficacy.
(
- Contribution to journal › Article
-
Mark
von Willebrand's disease: a report from a meeting in the Åland islands.
(
- Contribution to journal › Article
-
Mark
Models of prophylaxis.
(
- Contribution to journal › Article
-
Mark
New treatments in hemophilia: insights for the clinician.
(
- Contribution to journal › Article
-
Mark
Treatment of haemophilia A and B and von Willebrand's disease: summary and conclusions of a systematic review as part of a Swedish health-technology assessment.
(
- Contribution to journal › Article
-
Mark
Antibody formation and specificity in Bethesda-negative brother pairs with haemophilia A.
2012) In Haemophilia(
- Contribution to journal › Article
-
Mark
Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: a beneficial effect on orthopaedic outcome and quality of life.
(
- Contribution to journal › Article
-
Mark
Clinical trial design in haemophilia.
(
- Contribution to journal › Article
-
Mark
Modern haemophilia care.
(
- Contribution to journal › Article
-
Mark
Von Willebrand disease.
2012) In Pediatric Blood & Cancer(
- Contribution to journal › Article
-
Mark
The international factor IX treatment network survey.
(
- Contribution to journal › Letter
- 2011
-
Mark
Inhibitors in haemophilia A - Prevention, current management and personalised therapy perspectives
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Inhibitors in haemophilia A - Prevention, current management and personalised therapy perspectives
(
- Contribution to journal › Article
-
Mark
The pro-FEIBA study: prophylactic dosing of Factor Eight Inhibitor Bypassing Activity (FEIBA) reduces bleeding frequency in haemophilia a patients with inhibitors
(
- Contribution to journal › Published meeting abstract
-
Mark
The international factor IX treatment network survey
(
- Contribution to journal › Published meeting abstract
-
Mark
Haematuria and hypertension in haemophilia - the H3 study
(
- Contribution to journal › Published meeting abstract
-
Mark
Bone density and health-related quality of life in adult patients with severe haemophilia.
(
- Contribution to journal › Article
-
Mark
Anti-Inhibitor Coagulant Complex Prophylaxis in Hemophilia with Inhibitors
(
- Contribution to journal › Article
-
Mark
Optimizing patient therapy - optimal dosing: when is enough enough?
(
- Contribution to journal › Article
-
Mark
A consensus statement on clinical trials of bypassing agent prophylaxis in inhibitor patients.
(
- Contribution to journal › Article
-
Mark
Identifying non-responsive bleeding episodes in patients with haemophilia and inhibitors: a consensus definition.
(
- Contribution to journal › Article
-
Mark
Ovanliga ärftliga former av blödarsjuka. Blödningssymtom, familjehistoria och laboratorieanalyser ger diagnosen.
(
- Contribution to journal › Article
-
Mark
Safety and pharmacokinetics of subcutaneously administered recombinant activated factor VII (rFVIIa).
(
- Contribution to journal › Article
-
Mark
When von Willebrand disease comes into age - A matter of change?
(
- Contribution to journal › Article
-
Mark
Physical activity and joint function in adults with severe haemophilia on long-term prophylaxis.
(
- Contribution to journal › Article
-
Mark
Importance of rapid bleeding control in haemophilia complicated by inhibitors.
(
- Contribution to journal › Article
- 2010
-
Mark
Thrombin Generation Testing for Monitoring Hemophilia Treatment: A Clinical Perspective
(
- Contribution to journal › Article
-
Mark
Treatment of the critically ill patient with protein C: Is it worth the cost?
(
- Contribution to journal › Article
-
Mark
The role of prophylaxis in bleeding disorders
(
- Contribution to journal › Scientific review
-
Mark
Regular Replacement Therapy as Prophylaxis In Severe Forms of Von Willebrand Disease Initial Results From the Von Willebrand Disease Prophylaxis Network (VWD PN) Study Group
(
- Contribution to journal › Published meeting abstract
-
Mark
A retrospective study: of Octaplex (R) in the treatment of bleeding in patients with haemophilia A complicated by inhibitors
(
- Contribution to journal › Published meeting abstract
-
Mark
Von Willebrand disease prophylaxis network
(
- Contribution to journal › Published meeting abstract
-
Mark
FEIBA prophylaxis in haemophilia patients: a clinical update and treatment recommendations
(
- Contribution to journal › Article
-
Mark
The combination of Octaplex (R) and Octanate (R) restores thrombin generation capacity in FVIII inhibitor plasma in-vitro
(
- Contribution to journal › Published meeting abstract
-
Mark
The necessity of having FVIII in VWF concentrates
2010) 3rd Annual Congress of the European Association for Haemophilia and Allied Disorders In Haemophilia 16(2). p.400-400(
- Contribution to journal › Published meeting abstract
-
Mark
A prospective, randomized, and crossover study of an activated prothrombin complex concentrate for secondary prophylaxis in patients with hemophilia A and inhibitors (Pro-FEIBA): subject demographics and safety data
2010) XXIXth International Congress of the World Federation of Hemophilia In Haemophilia 16(Suppl. 4). p.31-31(
- Contribution to journal › Published meeting abstract
-
Mark
Mild haemophilia in Sweden
(
- Contribution to journal › Published meeting abstract
-
Mark
The international factor IX treatment network survey
2010) 3rd Annual Congress of the European Association for Haemophilia and Allied Disorders In Haemophilia 16(2). p.403-403(
- Contribution to journal › Published meeting abstract
-
Mark
Network activities were initiated in December, 2009, and will extend over the next five years. von Willebrand disease prophylaxis network
2010) 3rd Annual Congress of the European Association for Haemophilia and Allied Disorders In Haemophilia 16(2). p.403-403(
- Contribution to journal › Published meeting abstract
-
Mark
Safety of Recombinant Human Factor IX, Nonacog Alfa, for Usual Use In Pediatric Patients Results From a Prospective Registry of European Hemophilia B Patients
(
- Contribution to journal › Published meeting abstract
-
Mark
Influence of the pre-analytical specimen storage conditions on thrombin generation assay
2010) XXIXth International Congress of the World Federation of Hemophilia In Haemophilia 16(Suppl. 4). p.45-45(
- Contribution to journal › Published meeting abstract
-
Mark
F8 haplotype and recombinant product use in the Hemophilia Inhibitor Genetics Study (HIGS)
(
- Contribution to journal › Published meeting abstract
-
Mark
Prophylactic Dosing of Anti Inhibitor Coagulant Complex (FEIBA) Reduces Bleeding Frequency In Hemophilia A Patients with Inhibitors Results of the Pro FEIBA Study
(
- Contribution to journal › Published meeting abstract
-
Mark
Prophylaxis in von Willebrand disease
(
- Contribution to journal › Published meeting abstract
-
Mark
Assessment of health-related quality of life in patients with severe haemophilia with reduced bone density
(
- Contribution to journal › Published meeting abstract
-
Mark
Von Willebrands sjukdom--från biokemi till klinisk praxis.
(
- Contribution to journal › Scientific review
-
Mark
Thrombin generation in vitro in the presence of by-passing agents in siblings with severe haemophilia A.
(
- Contribution to journal › Article
-
Mark
Anti-prothrombin antibodies are associated with thrombosis in children.
(
- Contribution to journal › Article
-
Mark
Combination of FVIII and by-passing agent potentiates in vitro thrombin production in haemophilia A inhibitor plasma.
(
- Contribution to journal › Article
-
Mark
Physical activity for prevention of osteoporosis in patients with severe haemophilia on long-term prophylaxis.
(
- Contribution to journal › Article
-
Mark
A retrospective study of Octaplex in the treatment of bleeding in patients with haemophilia A complicated by inhibitors.
(
- Contribution to journal › Article
- 2009
-
Mark
Thrombin generation assay: a useful routine check-up tool in the management of patients with haemophilia?
(
- Contribution to journal › Article
-
Mark
The application of bypassing-agent prophylaxis in haemophilia A patients with inhibitors: a meeting report
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Genetic Factors Associated with Inhibitor Development in Hemophilia A: Initial Results From the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort
(
- Contribution to journal › Published meeting abstract
-
Mark
Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.
(
- Contribution to journal › Article
-
Mark
Physical activity as prevention of osteoporosis in patients with severe haemophilia on long term prophylaxis
2009) 14th Annual Meeting of the European-Hematology-Association In Haematologica-The Hematology Journal 94. p.0118-0118(
- Contribution to journal › Published meeting abstract
-
Mark
Arandomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study.
(
- Contribution to journal › Article
-
Mark
Thrombin generation after emergency contraception
2009) 3rd International Symposium on Womens Health Issues in Thrombosis and Haemostasis In Thrombosis Research 123. p.152-152(
- Contribution to journal › Published meeting abstract
-
Mark
Increased thrombin generation in women with a history of preeclampsia
(
- Contribution to journal › Article
-
Mark
Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimens.
(
- Contribution to journal › Article
-
Mark
Long-term prophylaxis in severe haemophilia seems to preserve bone mineral density.
(
- Contribution to journal › Article
-
Mark
Haemate P/Humate-P: a systematic review.
(
- Contribution to journal › Article
-
Mark
Lower incidence of procoagulant abnormalities during follow-up after creation of the Fontan circulation in children.
(
- Contribution to journal › Article
-
Mark
Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors.
(
- Contribution to journal › Article
- 2008
-
Mark
VWD type 3 - historical review and contemporary treatment dilemmas
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.111-111(
- Contribution to journal › Published meeting abstract
-
Mark
Value added: increasing the power to assess treatment outcome in joint haemorrhages
(
- Contribution to journal › Article
-
Mark
Thrombin generation assay: a useful tool in the management of haemophilia A patients?
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.26-26(
- Contribution to journal › Published meeting abstract
-
Mark
Genetic aspects of inhibitor development
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.21-21(
- Contribution to journal › Published meeting abstract
-
Mark
von Willebrand disease update: diagnostic and treatment dilemmas
(
- Contribution to journal › Article
-
Mark
Genetic aspects and research development in haemostasis
(
- Contribution to journal › Article
-
Mark
Bone density in hemophilia
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.79-79(
- Contribution to journal › Published meeting abstract
-
Mark
Effects of pentoxifylline and its metabolites on platelet aggregation in whole blood from healthy humans.
(
- Contribution to journal › Article
-
Mark
Surgical evaluation of a recombinant factorVIII prepared using a plasma/albumin-free method: Efficacy and safety of Advate in previously treated patients
(
- Contribution to journal › Article
-
Mark
A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate P/ Humate -P: history and clinical performance.
(
- Contribution to journal › Scientific review
-
Mark
High purity, double virus-inactivated VWF/FVIII concentrate in long term prophylaxis of von Willebrand disease - experience from prospective clinical trials and German post-licensure surveillance
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.12-12(
- Contribution to journal › Published meeting abstract